Subscribe To

Price Alert Latest News Economic Calendar News

GILD / Gilead Sciences shares decline after it discontinues blood cancer treatment trial

Gilead Sciences, Inc. (NASDAQ:GILD) started on the back foot on Monday after the biopharmaceutical company told investors it has discontinued its Phase 3 ENHANCE study of its investigational anti-CD47 antibody magrolimab for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS). Foster City, California-based Gilead said in a statement the decision to end the study was due to “futility based on a planned analysis. Read More

Demo Live Account See Partner Details

Content Topics

Gilead

Sciences

Decline

After

Discontinues

Blood

Cancer

Treatment

Stock

GILD

Posted: Jul 24 2023, 10:27

Author Name: Proactive Investors

GILD News

By Business Wire
November 3, 2023

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America

By Zacks Investment Research
October 30, 2023

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.

By Zacks Investment Research
October 30, 2023

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 resul

By Zacks Investment Research
October 24, 2023

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.

By InvestorPlace
October 20, 2023

7 Healthcare Stocks to invest in for a Healthy Future

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant develop

By Zacks Investment Research
October 19, 2023

GILD or VRTX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). Bu

By Market Watch
October 17, 2023

Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs

Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with

By Seeking Alpha
October 15, 2023

Gilead Sciences Stock Is Cheap, With Broad Pipeline

Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.